Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced ...

GoodRx reports on identifying real Wegovy pens, which come in five colors and lack dose selectors. Counterfeits pose health ...

Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid ...

GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark.

The researchers observed “significant” weight regain at eight, 12, and 20 weeks after discontinuation. They deduced that most patients gain back the weight they initially lost for an average of 20 ...

Tonight’s Hot Topic Tuesday revisits injectable weight-loss drugs and the new discoveries coming out about the medications.

Several anti-obesity drugs, including Ozempic, Wegovy and Mounjaro, have created buzz in the Indian markets. But are they really approved for use in India? What are their side-effects? And how much do ...

What happens when you stop taking Ozempic®? There’s no one-size-fits-all answer to this question. When you stop taking ...

Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year later, according to an analysis of U.S. pharmacy claims.

The researchers first tested their hypothesis by delivering ODN directly to the hindbrain of rats. Once treated, the rats ...

Weight loss injections could be key to controlling a chronic condition in thousands of Brits, new research suggests ...